Madhav Seshadri, MD
Assistant Professor
Medicine
School of Medicine

I take care of people with lymphoma and chronic lymphocytic leukemia. I believe in taking an individualized approach to each patient's care. By understanding their values and priorities, together we will arrive at the best treatment plan.

Show full bio (130 words) Hide full bio

I graduated with honors from Emory University School of Medicine in Atlanta. I completed residency in Internal Medicine and fellowship in Hematology and Oncology at New York Presbyterian Hospital/Weill Cornell Medical Center in New York, where I also served as Chief Fellow. At UCSF I am fortunate to practice at a leading medical center which is at the forefront of cancer care.

Technologies for the diagnosis and treatment of lymphoma and CLL are rapidly evolving, and I will use the latest advancements in providing care for patients. We are also fortunate to have a strong team of specialty consultants, nurse practitioners, nurses, medical technicians, pharmacists, and administrative staff. It would be a privilege to care for you or your family member.

Awards

Show all (3) Hide

• Research Training Award for Fellows, American Society of Hematology, 2021-2022
• Abstract Achievement Award, American Society of Hematology, 2021
• Ann Hoyt Jolley Merit Scholarship, Emory University School of Medicine, 2015-2016

Education & Training

Show all (5) Hide

• Chief Fellow, Hematology and Oncology New York-Presbyterian Hospital, Weill Cornell Medical Center 2022
• Fellowship, Hematology and Oncology New York-Presbyterian Hospital, Weill Cornell Medical Center 2022
• Residency, Internal Medicine New York-Presbyterian Hospital, Weill Cornell Medical Center 2019
• MD Emory University School of Medicine 2016
• BA Neuroscience Johns Hopkins University 2009

Interests

Show all (5) Hide

• Lymphoma
• Clinical research
• Cellular therapy (including CAR-T)
• Chronic lymphocytic leukemia
• Immunotherapy

Publications (10)

Top publication keywords:
ThrombopoietinHydrazinesMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinLymphoproliferative DisordersAntigens, CD19Epstein-Barr Virus InfectionsComplement Inactivating AgentsCell Transformation, NeoplasticLeukemiaHematopoietic Stem Cell TransplantationCellular MicroenvironmentLymphoma, Large B-Cell, DiffuseReceptors, ThrombopoietinNF-kappa BHematopoietic Stem Cells

• Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma.
  American journal of hematology 2024 Thiruvengadam SK, Merryman R, Wang Y, Gaulin C, Bezerra E, Voorhees T, Seshadri MR, Falade A, Habib A, Ayers AA, Bailey M, Brown A, Bailey N, Patel K, Andreadis CB, Kittai AS, Jacobson C, Palmer J, …
• Artificial Intelligence to Complement, Not Replace, Clinical Knowledge: Reading Between the Lines.
  JACC. CardioOncology 2024 Barrios JP, Seshadri MR, Tison GH
• Premortem Skin Biopsy Assessing Microthrombi, Interferon Type I Antiviral and Regulatory Proteins, and Complement Deposition Correlates with Coronavirus Disease 2019 Clinical Stage.
  The American journal of pathology 2022 Laurence J, Nuovo G, Racine-Brzostek SE, Seshadri M, Elhadad S, Crowson AN, Mulvey JJ, Harp J, Ahamed J, Magro C
• Ofatumumab for Post-Transplant Lymphoproliferative Disorder.
  Hematology/oncology and stem cell therapy 2022 Seshadri M, Crane GM, Gergis U
• Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
  Leukemia & lymphoma 2021 Seshadri MR, Melnick AM

Show all (5 more) Hide

• Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists.
  American journal of hematology 2021 Lee EJ, Seshadri M, Bussel JB
• Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
  Clinical immunology (Orlando, Fla.) 2020 Laurence J, Mulvey JJ, Seshadri M, Racanelli A, Harp J, Schenck EJ, Zappetti D, Horn EM, Magro CM
• Microenvironmental regulation of hematopoietic stem cells and its implications in leukemogenesis.
  Current opinion in hematology 2016 Seshadri M, Qu CK
• Image-guided thermal therapy with a dual-contrast magnetic nanoparticle formulation: A feasibility study.
  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2016 Attaluri A, Seshadri M, Mirpour S, Wabler M, Marinho T, Furqan M, Zhou H, De Paoli S, Gruettner C, Gilson W, DeWeese T, Garcia M, Ivkov R, Liapi E
• Snapin mediates incretin action and augments glucose-dependent insulin secretion.
  Cell metabolism 2011 Song WJ, Seshadri M, Ashraf U, Mdluli T, Mondal P, Keil M, Azevedo M, Kirschner LS, Stratakis CA, Hussain MA